Regenerative Medical Technology Group Inc
regenmedtechgroup.comRegenerative Medical Technology Group Inc (OTC: RMTG) is a regenerative medicine company that combines physician education, biologic product manufacturing, and direct patient care through a vertically integrated structure operating primarily in Mexico, Argentina, and other international markets. Revenue is generated through high-ticket clinical procedures at its Cellular Institute in Cancún, Mexico; sales of its proprietary Cellgenic product portfolio including stem cell therapies, exosomes, and peptides; and physician education and certification programs run through the International Society for Stem Cell Applications (ISSCA). The company operates through its subsidiary Global Stem Cells Group (GSCG) and serves medical professionals and patients seeking regenerative treatments. As of the filing date (May 14, 2026), RMTG carries approximately $16.6 million in secured debt subject to potential acceleration, holds unsecured promissory notes with aggregate principal of $1,157,935 currently in default, and has financed operations primarily through private placements, convertible notes, and unsecured debt since inception.
Products & Services
Cellgenic proprietary biologic and therapeutic product portfolio including stem cell therapies, exosomes, and peptides; Cellular Institute premium clinical services including anti-aging, biohacking, hormone therapy, aesthetic medicine, and advanced cellular therapies; ISSCA physician education programs spanning in-person international events (15 events across five continents in 2025), online certifications, specialty programs in orthopedics, aesthetics, and longevity, and the ISSCA Global Summit (attended by more than 470 medical professionals in 2025, held in Cancún); Stem Cell Center digital patient acquisition and referral platform; COFEPRIS-licensed stem cell collection center, stem cell bank, and advanced manufacturing facility in Cancún.
Revenue Model
Transactional and service-based revenue from high-ticket regenerative medicine procedures at the Cellular Institute (Cancún, Mexico); product sales of Cellgenic biologics (stem cell therapies, exosomes, peptides) to affiliated and independent clinics; physician education fees from ISSCA conferences, certifications, and online programs; and medical tourism patient referrals coordinated through the Stem Cell Center digital platform. The filing does not disclose segment revenue figures or percentages.
Customers & Markets
Physicians and medical professionals seeking regenerative medicine training and protocol certification; patients pursuing regenerative and anti-aging treatments, including international medical tourism patients; affiliated clinic networks integrating Cellgenic products and ISSCA protocols. End markets include regenerative medicine, aesthetic medicine, orthopedics, longevity and anti-aging, and advanced cell therapy. The filing does not disclose customer concentration data.
Geographic Exposure
Primary operations in Cancún, Mexico (Cellular Institute, manufacturing facility). Argentina identified as a key strategic market as of 2026, with compliant production and nationwide commercialization of Cellgenic products under Argentina's regulatory framework for advanced biologics. Expansion activity noted in Latin America and Southeast Asia as of 2025. ISSCA events conducted across five continents in 2025.
Financial Snapshot
Loading...
